References
- . Naranjo CA, Busto U, Sellers EM, . A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245
- . UpToDate.com. Silvergleid A, Schrier S, Landaw S. General principles of the use of intravenous immune globulin. http://www.uptodate.com. Accessed August 6, 2008
- . UpToDate.com. Berger M, Stiehm E, Feldweg, A. Use of immune globulin in primary immunodeficiency. http://www.uptodate.com. Accessed October 15, 2008
- . Orbach H, Tishler M, Shoenfeld Y. Intravenous immunoglobulin and the kidney—a two-edged sword. Semin Arthritis Rheum. 2004;34(3):593–601
- . Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol. 2005;29(3):173–184
- . Itkin Y, Trujillo TC. Intravenous immunoglobulin-associated acute renal failure: case series and literature review. Pharmacotherapy. 2005;25(6):886–892
- . Daphnis E, Stylianou K, Alexandrakis M, . Acute renal failure, translocational hyponatremia and hyperkalemia following intravenous immunoglobulin therapy. Nephron Clin Pract. 2007;106(4):c143–c148
- . Parazella, MA. Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity. Am J Med Sci. 2003;325(6):349–362
- . Chapman SA, Gilkerson KL, Davin TD, Pritzker MR. Acute renal failure and intravenous immune globulin: occurs with sucrose-stabilized, but not with D-sorbitol-stabilized formulation. Ann Pharmacother. 2004;38(12):2059–2067
- . Anderson W, Bethea W. Renal lesions following administration of hypertonic solutions of sucrose. JAMA. 1940;114(20):1983–1987
- . Dickenmann M, Oettl T, Mihatsch MJ. Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes. Am J Kidney Dis. 2008;51(3):491–503
- . Cayco AV, Perazella MA, Hayslett JP. Renal insufficiency after intravenous immune globulin therapy: a report of two cases and an analysis of the literature. J Am Soc Nephrol. 1997;8(11):1788–1794